Clinical Oncology
Volume 20, Issue 6 , Pages 448-456 , August 2008

The Role of Radical Surgery in Carcinoma of the Endometrium

  • C.M. Holland

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: C. Holland, University of Manchester Academic Unit of Obstetrics and Gynaecology, School of Cancer and Imaging Sciences, c/o Research Floor, St Mary’s Hospital, Whitworth Park, Manchester M13 0JH, UK. Tel: +44-1612766278; Fax: +44-1612766134.

Received 11 January 2008 ,Revised 11 March 2008 ,Accepted 28 March 2008.

References 

  1. International Federation of Gynaecology and Obstetrics . Corpus cancer staging. Int J Gynecol Obstet. 1989;28:189–190
  2. Kitchener HCRC, Swart AMC, Amos CL. ASTEC (surgery component): a study in the treatment of endometrial cancer. A randomized trial of lymphadenectomy in the treatment of endometrial cancer. ESGO 2005. Int J Gynecol Cancer. 2005;15(Suppl 2):77;[abstract 00094]
  3. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathological spread patterns of endometrial cancer — a gynecologic oncology group study. Cancer. 1987;60(8):2035–2041
  4. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG. 2007;114(11):1313–1320
  5. Creutzberg CL, van Putten WLJ, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89(2):201–209
  6. Gehrig PA, Van Le L, Fowler WC. The role of omentectomy during the surgical staging of uterine serous carcinoma. Int J Gynecol Cancer. 2003;13(2):212–215
  7. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma. Evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69(1):69–73
  8. Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105(3):677–682
  9. Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;107(2):186–189
  10. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95(3):593–596
  11. Abeler VM, Vergote IB, Kjorstad KE, Trope CG. Clear cell carcinoma of the endometrium — prognosis and metastatic pattern. Cancer. 1996;78(8):1740–1747
  12. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1272–1276
  13. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12(6):687–690
  14. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma — a Gynecologic Oncology Group study. Cancer. 1993;71(4):1702–1709
  15. Huh WK, Powell M, Leath CA, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003;91(3):470–475
  16. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44(2):265–272
  17. Holland CM, Shafi MI. Radical hysterectomy. Best Pract Res Clin Obstet Gynaecol. 2005;19(3):387–401
  18. Yura Y, Tauchi K, Koshiyama M, et al. Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters. Gynecol Oncol. 1996;63(1):114–119
  19. Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. Eur J Gynaecol Oncol. 2003;24(3–4):241–245
  20. Tamussino KF, Reich O, Gucer F, et al. Parametrial spread in patients with endometrial carcinoma undergoing radical hysterectomy. Int J Gynecol Cancer. 2000;10(4):313–317
  21. Kinsella T, Bloomer WD, Lavin PT, Knapp RC. Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment. Gynecol Oncol. 1980;10:290–297
  22. Larson DM, Copeland LJ, Gallager HS, Kong JP, Wharton JT, Stringer CA. Stage II endometrial carcinoma: results and complications of a combined radiotherapeutic-surgical approach. Cancer. 1988;61:1528–1534
  23. Calais G, Lefloch O, Descamps P, Vitu L, Lansac J. Radical hysterectomy for stage-I and stage-II endometrial carcinoma — a retrospective analysis of 179 cases. Int J Radiat Oncol Biol Phys. 1991;20(4):677–683
  24. Nahhas WA, Whitney CW, Stryker JA, Curry SL, Chung CK, Mortel R. Stage II endometrial carcinoma. Gynecol Oncol. 1980;10:303–311
  25. Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol. 1999;74(1):80–85
  26. Boothby RA, Carlson JA, Neiman W, et al. Treatment of stage-II endometrial carcinoma. Gynecol Oncol. 1989;33(2):204–208
  27. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol. 2001;83(1):72–80
  28. Sartori E, Gadducci A, Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001;11(6):430–437
  29. Boente MP, Yordan EL, McIntosh DG, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993;51(3):316–322
  30. Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988–1994. Gynecol Oncol. 1999;74(3):350–355
  31. Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepherd JH. FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat. 1998;3:35–62
  32. Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol. 1999;74(1):74–79
  33. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005;97(3):755–763
  34. Pliskow S, Penalver M, Averette HE. Stage III and stage IV endometrial carcinoma — a review of 41 cases. Gynecol Oncol. 1990;38(2):210–215
  35. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol. 1997;67(1):56–60
  36. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78(2):85–91
  37. Goff BA, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma — a study of 47 cases. Gynecol Oncol. 1994;52(2):237–240
  38. Hoskins WJ. Epithelial ovarian carcinoma — principles of primary surgery. Gynecol Oncol. 1994;55(3):S91–S96
  39. Memarzadeh S, Holschneider CH, Bristow RE, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002;12(5):454–458
  40. Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107(2):190–193
  41. Wylie J, Irwin C, Pintilie M, et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol. 2000;77(1):66–72
  42. Hoekstra CJM, Koper PCM, Vanputten WLJ. Recurrent endometrial adenocarcinoma after surgery alone — prognostic factors and treatment. Radiother Oncol. 1993;27(2):164–166
  43. Sears JD, Greven KM, Hoen HM, Randall ME. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer. 1994;74(4):1303–1308
  44. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol. 1996;60(2):288–291
  45. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75(1):99–102
  46. Nezhat F, Hayes MP, Peiretti M, Rahaman J. Laparoscopic radical parametrectomy and partial vaginectomy for recurrent endometrial cancer. Gynecol Oncol. 2007;104(2):494–496
  47. Scarabelli C, Campagnutta E, Giorda G, et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol. 1998;70(1):90–93
  48. Campagnutta E, Giorda G, De Piero G, et al. Surgical treatment of recurrent endometrial carcinoma. Cancer. 2004;100(1):89–96
  49. Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol. 2006;102(3):480–488
  50. Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006;103(1):281–287
  51. Mannel RS, Berman ML, Walker JL, Manetta A, Disaia PJ. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990;75(6):1016–1022
  52. Cunha TM, Felix A, Cabral I. Preoperative assessment of deep myometrial and cervical invasion in endometrial carcinoma: comparison of magnetic resonance imaging and gross visual inspection. Int J Gynecol Cancer. 2001;11(2):130–136
  53. Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation-therapy alone. Int J Radiat Oncol Biol Phys. 1993;27(4):817–824

PII: S0936-6555(08)00167-2

doi: 10.1016/j.clon.2008.03.012

Clinical Oncology
Volume 20, Issue 6 , Pages 448-456 , August 2008

Article Tools